



Manual: IU Health Plans
Department: Utilization Management
Policy # MP106
Effective Date: 11/01/2025
Last Revision: 06/01/2024

Health Plans

Medicare Advantage

X Commercial

GeneSight Testing Policy

I. Purpose

Indiana University Health Plans (IU Health Plans) considers clinical indications when making a medical necessity determination for GeneSight Testing.

II. Scope

This policy applies to all Utilization Management staff having decision-making responsibilities where authorization is required for Fully Insured commercial plans.

III. Exceptions

None

IV. Definitions

GeneSight: a test using genetic analysis to show how a person responds to different medications used to treat depression, anxiety, ADHD, and other psychiatric conditions.

V. Policy Statements

IU Health Plans considers **GeneSight Testing** is considered medically necessary and therefore covered when **ALL** of the following are met:

1. When ordered by an MD/DO who are board eligible or board certified in psychiatry, neuropsychiatry, or an advanced mental health practitioners (Mental Health Psychiatric Nurse Practitioners, Psychiatric Physician assistants) contemplating an alteration in neuropsychiatric medication for patients.
2. After failure of a trial of 2 medications as determined by the practitioner who has requested the test.

CODES

Code	Description
0345U	Proprietary Lab Analysis code for GeneSight Psychotropic testing

VI. Procedures

None

VII. References/Citations

1. Hoehe MR, Morris-Rosendahl DJ. The role of genetics and genomics in clinical psychiatry. *Dialogues Clin Neurosci*. 2018 Sep;20(3):169-177. doi: 10.31887/DCNS.2018.20.3/mhoehe. PMID: 30581286; PMCID: PMC6296395.
2. Peterson K, Dieperink E, Ferguson L, et al. Evidence Brief: The Comparative Effectiveness, Harms, and Cost-effectiveness of Pharmacogenomics-guided Antidepressant Treatment versus Usual Care for Major Depressive Disorder [Internet]. Washington (DC): Department of Veterans Affairs (US); 2016 May. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK384610/>
3. Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, Nemeroff CB. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing. *Am J Psychiatry*. 2018 Sep 1;175(9):873-886. doi: 10.1176/appi.ajp.2018.17111282. Epub 2018 Apr 25. PMID: 29690793; PMCID: PMC6774046.

VIII. Forms/Appendices

None

IX. Responsibility

Medical Director

This Policy is proprietary and confidential. No part of this Policy may be disclosed in any manner to a third party without the prior written consent of IU Health Plans, Inc.